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Abstract
Background: High grade HPV infections and persistence are the strongest risk factors for cervical
cancer. Nevertheless other genital microorganisms may be involved in the progression of HPV
associated lesions.
Methods: Cervical samples were collected to search for human Papillomavirus (HPV), bacteria and
yeast infections in gynaecologic outpatients. HPV typing was carried out by PCR and sequencing on
cervical brush specimens. Chlamydia trachomatis was identified by strand displacement amplification
(SDA) and the other microorganisms were detected by conventional methods.
Results: In this cross-sectional study on 857 enrolled outpatients, statistical analyses revealed a
significant association of HPV with C. trachomatis and Ureaplasma urealyticum (at high density)
detection, whereas no correlation was found between HPV infection and bacterial vaginosis,
Streptococcus agalactiae, yeasts, Trichomonas vaginalis and U. urealyticum. Mycoplasma hominis was
isolated only in a few cases both in HPV positive and negative women and no patient was infected
with Neisseria gonorrhoeae.
Conclusion: Although bacterial vaginosis was not significantly associated with HPV, it was more
common among the HPV positive women. A significant association between HPV and C. trachomatis
was found and interestingly also with U. urealyticum but only at a high colonization rate. These data
suggest that it may be important to screen for the simultaneous presence of different
microorganisms which may have synergistic pathological effects.
Background
Infection with high grade Human papillomavirus (HPV)
plays a central role in cervical carcinogenesis. Epidemio-
logical and molecular investigations have shown une-
quivocally that high grade HPV infection is the main
causal factor in initiating the progressive transformation
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vical cancer [1,2]. Many reports have demonstrated that
HPV infections are mostly transitory and that only a small
percentage of infections persist and may progress to dys-
plastic cervical lesions: type-specific HPV persistence is the
strongest risk factor for cervical cancer [3]. The reasons for
the variable natural history remain poorly understood but
it has been generally accepted that different cofactors are
involved in the development of dysplasia in HPV infected
women. Factors, such as specific HPV genotype, viral load,
and co-infection with more HPV types, are likely to be
involved in the progression to precancerous cervical
lesions [4-6]. In addition, environmental factors [7-9]
including smoking, long term hormone contraceptives
and co-infection with other microorganisms have also
been investigated as potentially involved in the disease
process. The sexually transmitted agents that have shown
some evidence of an association with cervical dysplastic
and neoplastic lesion are Chlamydia trachomatis [10] and
Herpes simplex virus (HSV) [11,12], although the specific
role of these microorganisms in the pathogenesis of cervi-
cal cancer has not been completely clarified.
The aim of this cross-sectional study was to evaluate the
prevalence of co-infection HPV and other genital microor-
ganisms: Chlamydia trachomatis, Neisseria gonorrhoeae,
Streptococcus agalactiae, Mycoplasma spp, Trichomonas vagi-
nalis. Yeasts and bacterial vaginosis were also investigated.
Methods
Study population
Women attending clinics for routine gynaecologic care in
the Department of Gynaecology, Perinatology and Child
Health of "Sapienza" University in Rome, between 2000
and 2006 were included in this study. Informed consent
was obtained from all women and this study was
approved by the Ethics Committees and/or Institutional
Review Boards of the participating institution. Cervical
samples were taken by cytobrush from the ectocervix and
from the endocervix for cytological analysis, detection of
HPV DNA and bacteriological tests. Cytology was classi-
fied according to the Bethesda system, using standard
forms and classified as negative, atypical squamous cell of
undetermined significance (ASCUS), atypical glandular
cell of undetermined significance (AGUS), low-grade
intraepithelial lesion (LSIL) or high-grade (HSIL) catego-
ries [13]. All the samples were analysed independently by
two cyto-technologists and the final diagnosis was based
on the consensus of both. Women were eligible for the
study if they: were not currently pregnant nor planning to
become pregnant for a year; had an intact uterus and no
current referral for hysterectomy; reported no use of vagi-
nal medication in the previous 3 days; reported no treat-
ment for cervical disease in the previous 6 months;
answered a structured questionnaire on socio-demo-
graphic characteristics, sexual behaviour, reproductive
history and smoking habits; provided samples adequate
for PCR assays and sequencing. According to these criteria,
857 women were enrolled in this cross-sectional study.
HPV detection and typing
Cervical brush samples collected in Phosphate Saline
Buffer (PBS) were centrifuged at low speed and the cell
pellets underwent DNA extraction using QIAampTissue
kit (Qiagen, Milan-Italy). Human Leukocyte Antigen
(HLA)-specific primers were used in polymerase chain
reaction (PCR) analysis to assess the suitability of the tar-
get DNA (9). A 450 bp fragment from the L1 region of
HPV-DNA was amplified using the consensus primer
MY09/11 as described elsewhere [14]. Four pairs of
degenerated consensus primers (able to detect 36 HPV
types) were used concomitantly to amplify the complete
E6 gene and part of the E7 gene [15], thus allowing the
detection of a broader range of HPV genotypes. The PCR
products were detected by ethidium bromide staining
after electrophoretic migration through 2% agarose gels.
HPV-positive reactions were purified using a QIAquick
PCR purification kit (QIAGEN), and an automatic DNA
sequencer (Applied Biosystems, Foster City, CA) was used
for sequencing utilising the PCR forward primer(s).
Sequence homology was determined using BLAST (NCBI




Streptococcus agalactiae (group B) strains were identified
from clinical samples by being weakly beta-haemolytic on
Columbia CNA Agar A (Oxoid). The suspected colonies
were serologically confirmed (Lancefield's classification)
[16,17].
Chlamydia trachomatis
endocervical swabs were tested for the presence of C. tra-
chomatis using the BD ProbeTec ET Assays (BDPT, Becton
Dickinson and Company, Franklin Lakes, NJ) according
to the manufacturer's instructions. This method amplifies
DNA from C. trachomatis in separate wells and optionally
can monitor inhibition of amplification for each speci-
men using strand displacement amplification (SDA) and
detection by fluorescent energy transfer (FRET) probes,
producing a method-other-than-acceleration (MOTA)
score for each specimen. Specimen processing and BDPT
performance followed the manufacturer's instructions.
The original algorithm involved retesting specimens with
MOTA scores between 2000 and 9999. A negative repeat
result (MOTA score <2000) was considered indetermi-
nate.Page 2 of 7
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presumptive identification of N. gonorrhoeae was carried
out by growth on media selective for pathogenic Neisseria
species (Oxoid) incubated for up to 48 hours in 5–10%
CO2 at 35–37°C. Colonies obtained were identified by
API NH (bioMerieux) according to manufacturer's
instructions.
Mycoplasma spp
Mycoplasma IST 2 (bioMérieux) was used for the isola-
tion of Mycoplasma hominis and Ureaplasma urealyticum
according to the manufacturer's instructions. The diagnos-
tic kit provided information regarding the presence or
absence of M. hominis and U. urealyticum and an estimate
of the density of each organism (cut-off 104-colour-chang-
ing units- CCU/ml) together with its antimicrobial sus-
ceptibilities to doxycycline, josamycin, ofloxacin,
erythromycin, tetracycline, pristinamycin, azithromycin,
clarythromycin, ciprofloxacin.
Candida spp
cervical-vaginal samples were cultured on Sabouraud dex-
trose agar (Oxoid) aerobically at 37°C for 24–48 h
[16,17]. The identity of clinical isolates was confirmed by
conventional mycological methods [18,19], such as the
germ tube induction test in serum (C. albicans or C. dub-
liniensis), microscopic morphology, and growth on Oxoid
Chromogenic Candida Agar (Oxoid) [18].
Non-Candida albicans yeast isolates were further speci-
ated with API 20C AUX or API 32C.
Trichomonas vaginalis
the vaginal swab was placed in 0.2 ml of sterile physio-
logic saline for wet mount evaluation and examined
microscopically (400×) within 15 min for motile tri-
chomonads.
The culture was carried out on Oxoid's Trichomonas
Medium n.2 for the recovery of T. vaginalis and incubated
aerobically a 37°C. The broth was examined microscopi-
cally for motile trichomonads on days 1, 3 and 5 [16,17].
Bacterial vaginosis
the presence of bacterial vaginosis was evaluated micro-
scopically on samples collected from the posterior vaginal
fornix. Bacterial vaginosis was diagnosed by the presence
of three of the clinical and microscopic findings standard-
ized by Amsel et al [20]: vaginal pH greater than 4.5; pres-
ence of clue cells; grey homogenous vaginal discharge;
positive Whiff-test in which a fishy odour is released after
the addition of 10% potassium hydroxide solution to vag-
inal fluid.
Statistical analysis
The χ2 test was used in the statistical analysis, while the
Odd Ratio was used to measure the strength of the associ-
ation with HPV. Statistical tests were considered signifi-
cant if the p value was 0.05 or less. Logistic regression
analysis was used to assess the simultaneous effect of
more than one variable on the risk of HPV infection and
to identify possible confounding factors.
Results
Study group characteristics
Out of 857 enrolled outpatients, two groups of patients
were identified on the basis of HPV DNA test positivity.
The demographic and behavioural characteristics of the
study population (266 HPV positive and 591 HPV nega-
tive women) are presented in table 1. The women were
aged between 17 and 57 years (mean 32.7 years). As
expected, the features significantly associated with HPV-
DNA detection in univariate analysis were: young
patient's age; age at first intercourse; high number of life-
time sexual partners. Smokers were 29.98% in the total
population with a significantly higher percentage in HPV
positive group (38.1% vs. 28.0; p = 0.003). HPV-DNA
detection was significantly higher in the nullipara women
and in those without spontaneous abortion. Only 22.40%
of the study participants usually use at least one contra-
ceptive method with no significant differences in HPV
positivity.
HPV genotyping
HPV genotypes found in samples from HPV positive
women were shown in table 2. Thirty-five different HPV
types were identified: HPV16 was the most prevalent
(14.50%), followed by HPV58 (9.16%), HPV53 (8.01%)
and HPV42 (6.10%); whereas each other genotype was
present in less than 5% of HPV positive women. In addi-
tion there were 4 cases of "missed typing" (1.5%), proba-
bly due to mixed infections with different HPV genotypes.
Moreover it should be considered that PCR amplification
and sequencing detect precisely the more abundant (and
probably clinically relevant) type and underestimate co-
infections. According to the reclassification proposed by
Munoz et al. (2006) [3], the aggregated percentage (HR
and probably HR) of detected HPV was 58.77%, 27.86%
for low-risk and 13.35% for unknown-risk HPV types. Of
the HPV negative women, 2.3% revealed an abnormal cer-
vical cytology (2% LG-SIL; 0.3% HG-SIL). Among HPV
positive women more than 60% had normal cytology,
whereas only 3.98% had HG-SIL. LG-SIL and ASCUS were
found in 29.8% and 3.1% respectively of HPV positive
women.Page 3 of 7
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In the total population, C. trachomatis was revealed in
8.05% of the samples, U. urealyticum was present in
28.35% and S. agalactiae in 8.86%; T. vaginalis was found
only in 1.16%, bacterial vaginosis in 6.30%, and yeast in
13.06%.
M. hominis was isolated only in a few cases whereas N.
gonorrhoeae was never found.
Co-infection HPV-other microorganisms
The detection of genital infections in the HPV negative
population was not infrequent: in fact S. agalactiae was
Table 1: Characteristics of studied groups: univariate analysis of age, sexual, reproductive and behavioural history.
HPV(+) HPV(-) Total HPV(+) % Comparison* 95% CI significance
TOTAL: frequency 266 591 857 31.0%
Age
mean age (years) (sd) 31.1(8.0) 33.5(7.5) 32.7(7.6) diff. -2.4 -1.3 to -3.5 t = -4.26,
P < 0.00005
Frequency:
<25 years 63 72 135 46.7% OR = 1.00
25- years 58 116 174 33.3% OR = 0.57 0.36 to 0.91 P = 0.017
30- years 68 142 210 32.4% OR = 0.55 0.35 to 0.85 P = 0.008
35- years 36 144 180 20.0% OR = 0.29 0.17 to 0.47 P < 0.00005
40+ years 41 117 158 25.9% OR = 0.40 0.25 to 0.65 P = 0.0003
Age at 1st intercourse
mean age (years) 18.6 19.6 19.3 diff. -1.01 -0.49 to -1.54 t = -3.79,
P = 0.0002
Frequency:
<16 years 25 42 67 37.3% OR = 1.00
16 years 34 55 89 38.2% OR = 1.04 0.54 to 2.00 P = 0.91
17 years 44 73 117 37.6% OR = 1.01 0.54 to 1.88 P = 0.97
18 years 58 115 173 33.5% OR = 0.85 0.47 to 1.52 P = 0.58
19 years 36 55 91 39.6% OR = 1.10 0.57 to 2.11 P = 0.77
20 years 21 87 108 19.4% OR = 0.41 0.20 to 0.81 P = 0.01
21 years 15 24 39 38.5% OR = 1.05 0.47 to 2.37 P = 0.91
22+ years 33 140 173 19.1% OR = 0.40 0.21 to 0.74 P = 0.004
Number of partners
mean 4.20 2.83 3.26 diff. 1.37 0.96 to 1.79 t = 6.51,
P < 0.00005
frequency:
1 partner 39 234 273 14.3% OR = 1.00
2 partners 46 129 175 26.3% OR = 2.14 1.33 to 3.45 P < 0.00005
3 partners 58 86 144 40.3% OR = 4.05 2.52 to 6.51 P < 0.00005
4 partners 41 42 83 49.4% OR = 5.86 3.39 to 10.13 P < 0.00005
5–9 partners 54 75 129 41.9% OR = 4.32 2.65 to 7.03 P < 0.00005
10+ partners 28 25 53 52.8% OR = 6.72 3.55 to 12.71 P < 0.00005
Parity
Nulliparous 215 432 33.2% OR = 1.00
Parous 51 159 24.3% OR = 0.64 0.45 to 0.92 P = 0.0154
Spontaneous abortion
No 238 485 723 32.9% OR = 1.00
Yes 28 106 134 20.9% OR = 0.54 0.35 to 0.84 P = 0.0063
Induced abortion
No 227 493 720 31.5% OR = 1.00
Yes 39 98 137 28.5% OR = 0.86 0.58 to1.29 P = 0.48
Contraceptives
never used any type 210 455 665 31.5% OR = 1.00
have used at least one type 56 136 192 29.2% OR = 0.89 0.63 to 1.27 P = 0.52
Smoking
never smoked 168 432 600 28.0% OR = 1.00
ever smoked 98 159 257 38.1% 1.58 1.17 to 2.16 P = 0.003
*diff. is the difference between two mean values and OR is the odds ratio compared with the first category.Page 4 of 7
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nosis in 5.2%, C. trachomatis in 5.4% and U. urealyticum in
24.8%. Generally U. urealyticum is a common commensal
of the female lower genital tract and it seems to be an
important opportunistic pathogen during pregnancy and
in other genital diseases such as cervicitis. Its pathogenic
potential seems to be related to the high density in the
analysed samples (>10,000 CCU/ml). In HPV negative
patients the percentage of U. urealyticum > 10,000 CCU/
ml was 5.24% (table 3).
The number of the specimens in which T. vaginalis was
detected was very low in both populations (1.12% in HPV
positive women vs. 1.18%).
Statistical analyses did not reveal any association between
HPV presence and S. agalactiae, yeasts, T. vaginalis and U.
urealyticum < 10,000 CCU/ml detection.
Although the bacterial vaginosis was diagnosed in a
higher percentage among HPV positive women (8.6% vs.
5.2% control group), the difference in the prevalence of
bacterial vaginosis was not statistically significant
between the 2 groups.
A significant association between HPV-DNA presence and
concurrent genital infection with C. trachomatis (p <
0.001) was observed (table 3). Interestingly, among HPV
positive women co-infected by C. trachomatis 67.56%
belonged to the HR-HPV infected patients.
Table 2: Genotypes in HPV positive women.
Risk category*
HIGH: total %
HPV type 16 18 31 33 35 45 51 52 56 58 59
Frequency 38 7 13 8 2 1 5 8 5 24 3 114 43.51
Probably HIGH:
HPV type 53 66 68 73
frequency 21 12 1 6 40 15.27
LOW:
HPV type 6 11 42 43 44 54 61 70 72 81 91
frequency 13 6 16 1 2 11 6 10 1 5 2 73 27.86
UNKNOWN:
HPV type 30 34 62 67 74 84 85 86 87
frequency 3 3 1 2 5 7 2 2 10 35 13.36
*According to Munoz et al. (2006) [3], 11 types were classified as high risk, 4 types as probably high-risk; 11 were classified as low-risk. Nine types 
were grouped as unknown-risk HPV because of their incomplete characterization due to their rare detection or recent identification.
Table 3: Different microorganisms infection in HPV positive and negative women
HPV(+) HPV(-) Total % positive odds ratio 95% CI Significance
C. trachomatis
negative 229 559 788 29.0% OR = 1.00
Positive 37 32 69 53.6% OR = 2.82 1.74 to 4.57 P < 0.00005
U. urealyticum
negative 170 444 614 27.7% OR = 1.00
<10000 CCU/ml 61 116 177 34.5% OR = 1.37 0.96 to 1.96 P = 0.08
>10000 CCU/ml 35 31 66 53.0% OR = 2.95 1.79 to 4.85 P < 0.00005
S. agalactiae
negative 246 535 781 31.5% OR = 1.00
Positive 20 56 76 26.3% OR = 0.78 0.46 to 1.32 P = 0.35
Yeasts
negative 234 511 745 31.4% OR = 1.00
Positive 32 80 112 28.6% OR = 0.87 0.56 to 1.35 P = 0.55
Bacterial vaginosis
negative 243 560 803 30.3% OR = 1.00
Positive 23 31 54 42.6% OR = 1.71 0.98 to 2.98 P = 0.06
T. vaginalis
negative 263 584 847 31.1% OR = 1.00
Positive 3 7 10 30.0% OR = 0.95 0.24 to 3.71 P = 0.94Page 5 of 7
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between the HPV positivity and the presence of U. urealyti-
cum > 10,000 CCU/ml (p < 0.001) (table 3).
Logistic regression analyses did not substantially change
these results.
Discussion
Our findings confirm that an increased risk of HPV infec-
tion is strongly associated with a young age at first inter-
course, and with an elevated number of sexual partners as
would be expected for a sexually transmitted viral infec-
tion.
Epidemiological studies have demonstrated the role of
other sexually transmitted infectious agents in the patho-
genesis of cervical cancer, but knowledge about the spe-
cific role of these pathogens in the natural history of HPV
infection is limited. There are several mechanisms by
which these co-infections may act, such as direct genotox-
icity, but probably the most likely biologic mechanism is
the induction of cervical inflammation leading genotoxic
damage through oxidative metabolites [21]. An associa-
tion between cervical cancer and C. trachomatis has been
established [22]. In fact, C. trachomatis infection may
increase susceptibility to HPV causing microabrasions or
alterations of epithelial cells thus facilitating the entry of
virions. Some reports have suggested that concurrent C.
trachomatis infection can reduce host ability to resolve
HPV infection: chronic cervical inflammation seems to
influence the HPV persistence through a raised produc-
tion of free radicals and a reduction of host cell-mediated
immunity [2,10]. C. trachomatis infection induces a shift
in the immune response and the unresolved infections
have been associated with a humoral (T helper cell type 2)
immune response, whereas cellular (T helper cell type 1)
immune response is important for the clearance of HPV
lesions. Therefore, the modulation of cervical immune
response by C trachomatis may influence the clearance of
HPV lesions [10].
Our data showed, in HPV positive patients, particularly in
HR HPV positive women, an increased C. trachomatis
infection rate; this result may suggest more accurate
screening for C. trachomatis in HPV positive patients with
an atypical cytology. Since both pathogens are co-varia-
bles related to sexual behaviour, probably they synergize
in inducing cervical epithelium alterations [3,23].
An increased infection rate of U. urealyticum in HPV posi-
tive group was also observed, but a significant association
was found only with high density cervical presence. The
biological role of U. urealyticum infection in the HPV out-
come was not previously clarified, but high level of U. ure-
alyticum seems to be a cofactor in the development of HPV
related cervical dysplasia [24]. It is tempting to speculate
that the presence of U. urealyticum may play a role both in
initiating cellular anomalies and in viral persistence. It
was reported that Mycoplasma infections cause in vitro
chromosomal changes and cell transformation through-
out gradual progressive chromosomal loss and transloca-
tions [25]. Robertsonian chromosome translocation has
been identified in the presence of Mycoplasma infections
[26].
Previous researches have produced conflicting results
regarding the role of bacterial vaginosis as cofactor in the
development of cervical intraepithelial neoplasia [27].
Thus, although bacterial vaginosis may have an influence
in acquisition of genital infections, its role into HPV
acquisition and persistence remains to be clarified [28].
Moreover, to date the only prospective study on bacterial
vaginosis and HPV infection, showed that both infections
occur simultaneously [29] and suggested that the presence
of HPV may have an influence in the vaginal flora. In our
findings, bacterial vaginosis is not statistically associated
with HPV infection, even if alterations of vaginal flora
tend to be more common among HPV positive than HPV
negative women (8.6% vs. 5.2% respectively).
This study evidenced also the lack of protective precau-
tions against sexually transmitted infections, both in HPV
positive and HPV negative women. Despite the use of con-
dom is not reported to be highly effective in reducing HPV
transmission [30,31], counselling on sexually transmitted
diseases (STDs) prevention use should be continued, for
instance, to prevent C. trachomatis transmission.
Conclusion
In this study a statistically significant association between
HPV and C. trachomatis was found and interestingly also
with U. urealyticum at a high colonization rate. Although
bacterial vaginosis was not significantly associated with
HPV, it was more common among HPV positive women.
These data confirm that screening for genital infections
may be important to reveal the simultaneous presence of
different sexually transmitted microorganisms. These
results suggest and emphasize the value of the screening
for genital infections in HPV positive patients in order to
decrease the presence of other microorganisms and to
reduce the probable synergistic effects of co-infections.
Prevention is important not only to avoid other STDs and
their sequelae, but also to reduce the influence of concom-
itant microorganisms on HPV infection.
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